Evidence map›Paper›PMID 41876395›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Accelerated 3D MRI for ARIA monitoring in Alzheimer's disease.

Miguel Rosa-Grilo, Dermot Mallon, David L Thomas, Millie Beament, Haroon R Chughtai, Wei Liu, Nicholas Magill, Ian B Malone, Heiko Meyer, Geoff J M Parker and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Miguel Rosa-GriloDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Dermot MallonLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK.
David L ThomasDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Millie BeamentDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Haroon R ChughtaiUCL Hawkes Institute, University College London, London, UK.
Wei LiuResearch & Clinical Translation, Magnetic Resonance, Siemens Healthineers AG, Erlangen, Germany.
Nicholas MagillDepartment of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
Ian B MaloneDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Heiko MeyerResearch & Clinical Translation, Magnetic Resonance, Siemens Healthineers AG, Erlangen, Germany.
Geoff J M ParkerUCL Hawkes Institute, University College London, London, UK.
Christina TriantafyllouResearch and Scientific Collaboration, Siemens Healthcare Ltd, Camberley, UK.
Frederik BarkhofLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK.
Nick C FoxDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Catherine J MummeryDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.

Funding

Alzheimer's Society Heather Corrie Impact Fund 577 [AS-PG-21-045]Biogen Idec UKNational Institute for Health and Care Research University College London Hospitals Biomedical Research CentreRosetrees Trust CF-2022-2/128
6 · The paper itself

Abstract

introductionAmyloid-targeting therapies for Alzheimer's disease require regular MRI monitoring for amyloid-related imaging abnormalities (ARIA). 3D scans are more sensitive but time intensive; ultra-fast implementations could improve access and reduce burden.

methodsEighty scans from 20 participants were acquired with standard 2D fluid-attenuated inversion recovery (FLAIR) and T2*-gradient recalled echo (T2*-GRE), or accelerated Wave-controlled aliasing in parallel imaging (Wave-CAIPI) 3D FLAIR and susceptibility-weighted imaging (SWI) at 3 T. Two neuroradiologists graded ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposits). Bayesian models estimated sensitivity, specificity, severity agreement, and interchangeability between acquisitions.

resultsAccelerated sequences reduced acquisition time by up to 56%. Four participants had ARIA-E and microbleeds; five had microbleeds alone. Sensitivity and specificity for ARIA-E were identical (1.00; 0.94-0.95); severity was comparable. Replacing standard with accelerated FLAIR did not decrease severity agreement (interchangeability 1.4; 95% highest-density interval [HDI] -3.6% to 5.4%). Fast SWI showed higher microbleed severity gradings. DISCUSSION: Wave-CAIPI offers fast high-resolution FLAIR acquisitions with comparable performance for ARIA-E monitoring. Wave-CAIPI SWI provides high-quality scans that may aid ARIA-H interpretation.

Indexed as

Alzheimer DiseaseBrainImaging, Three-DimensionalMagnetic Resonance ImagingAgedAged, 80 and overBayes TheoremFemaleHumansMaleSensitivity and Specificityadvanced parallel imagingAlzheimer's diseaseamyloid‐related imaging abnormalitiesMRI acceleration techniquesstructural MRIWave‐CAIPI

Identifiers

PMID41876395
PMCPMC13093291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.